CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
Schalekamp
Tom
T
Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. t.schalekamp@pharm.uu.nl
Boink
Gerard J J
GJ
Visser
Loes E
LE
Stricker
Bruno H Ch
BH
de Boer
Anthonius
A
Klungel
Olaf H
OH
D000074:Acenocoumarol / Q000008:administration & dosage / Q000009:adverse effects*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000453:epidemiology / Q000235:genetics*; D003362:Cost-Benefit Analysis; D065729:Cytochrome P-450 CYP2C9; D005838:Genotype; D006801:Humans; D019934:International Normalized Ratio / Q000191:economics*; D015233:Models, Statistical; D009426:Netherlands / Q000453:epidemiology
D000925:Anticoagulants; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000074:Acenocoumarol